Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat 5 mg initiation dose in chronic HFrEF
NCT06195930Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of Vericiguat oral suspension (Formulation 4) in heart failure with reduced ejection fraction (HFrEF), sponsored by Bayer. Started Apr 2024; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06195930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195930.